ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Therapeutic Drug Carrier Systems
インパクトファクター: 2.414 5年インパクトファクター: 3.324 SJR: 0.573 SNIP: 0.551 CiteScore™: 2.43

ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X

巻:
巻 36, 2019 巻 35, 2018 巻 34, 2017 巻 33, 2016 巻 32, 2015 巻 31, 2014 巻 30, 2013 巻 29, 2012 巻 28, 2011 巻 27, 2010 巻 26, 2009 巻 25, 2008 巻 24, 2007 巻 23, 2006 巻 22, 2005 巻 21, 2004 巻 20, 2003 巻 19, 2002 巻 18, 2001 巻 17, 2000 巻 16, 1999 巻 15, 1998 巻 14, 1997 巻 13, 1996 巻 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025459
pages 59-91

Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies

Preshita Desai
Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA
David Ann
Department of Diabetes Complications and Metabolism, City of Hope, Duarte, California, USA
Jeffrey Wang
Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA
Sunil Prabhu
Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA

要約

Pancreatic cancer is the fourth leading cause of death in the United States and has a 5-year life expectancy of ~8%. Currently, only a few drugs have been approved by the United States Food and Drug Administration for pancreatic cancer treatment. Despite available drug therapy and ongoing clinical investigations, the high prevalence and mortality associated with pancreatic cancer mean that there is an unmet chemopreventive and therapeutic need. From ongoing studies with various novel formulations, it is evident that the development of smart drug delivery systems will improve delivery of drug cargo to the pancreatic target site to ensure and enhance the therapeutic/chemoprevention efficacy of existing drugs and newly designed drugs in the future. With this in view, nanotechnology is emerging as a promising avenue to enhance drug delivery to the pancreas via both passive and active targeting mechanisms. Research in this field has grown extensively over the past decade, as is evident from available scientific literature. This review summarizes the recent advances that have brought nanotechnology-based formulations to the forefront of pancreatic cancer treatment.


Articles with similar content:

Long-Acting Injectables: Current Perspectives and Future Promise
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 2
Komal Chaudhary, Mayur M. Patel, Priti J. Mehta
Progress in Lipid-Based Nanoparticles for Cancer Therapy
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Eliahu Heldman, Charles Linder, Sarina Grinberg
Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.35, 2018, issue 1
Niyati S. Acharya, Namdev L. Dhas, Ritu R. Kudarha, Sanjeev R. Acharya
Critical Aspects in Rationale Design of Fluorouracil-Based Adjuvant Therapies for the Management of Colon Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 2
Vivek Ranjan Sinha, Honey
Emerging Role of Vesicular Carriers for Therapy of Visceral Leishmaniasis: Conventional versus Novel
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 6
Navneet Kumar, Suresh P. Vyas, Anuradha Dube, Swati Gupta